India’s Pharma Exports Surge to USD 23.1 Billion: Beyond the Horizon of Traditional Markets

India’s pharmaceutical sector has hit a significant milestone, with exports reaching USD 23.1 billion during the April–December period of the 2025–26 fiscal year. This 6.4% growth from the USD 21.7 billion recorded in the previous year highlights a pivotal shift in India’s trade strategy: strategic geographic diversification.

While the United States remains the largest single destination, the real momentum is now coming from a “Global South” surge, significantly reducing the industry’s historical dependence on a few mature markets.

The New Growth Engines: Africa and Latin America

Emerging markets have become the primary drivers of incremental export growth, contributing over 22% of the total increase this year.

Nigeria: The standout performer, accounting for 14.3% of the growth. Demand is surging for affordable generics, anti-infectives, and essential medicines as the nation expands its healthcare infrastructure.
Brazil: Contributed 7.9% to the growth, driven by a high volume of Finished Dosage Formulations (FDFs) and Active Pharmaceutical Ingredients (APIs).
Wider Footprint: Notable gains were also recorded in Australia, Canada, Russia, and the Netherlands. The Netherlands, in particular, has emerged as a strategic “Gateway to Europe,” adding over USD 58 million in incremental exports.

Performance of Mature Markets

In contrast to the double-digit growth in emerging regions, traditional hubs showed a more stabilized profile:

United States: Contributed roughly 4% to the growth. Despite being the largest market (accounting for ~31% of total exports), it faces persistent pricing pressures and intense regulatory scrutiny.
United Kingdom & Belgium: Shipments remained largely flat or saw marginal declines, reflecting a saturated market environment.

Why the Shift? Key Success Drivers

Industry analysts point to a combination of domestic policy and global reliability:

PLI Schemes: The Production Linked Incentive (PLI) schemes for Bulk Drugs and Pharmaceuticals have turned India into a net exporter of bulk drugs (surplus of ₹2,280 crore in FY 2024-25), reducing the dependency on raw material imports.
Quality & Compliance: India now hosts the largest number of USFDA-compliant plants outside the US, boosting global confidence in “Made in India” labels.
Supply Chain Resilience: Post-2024 global trade realignments have positioned India as a stable alternative to other major manufacturing hubs.
Affordability: The high demand for generic versions of GLP-1 agonists (for diabetes/obesity) and cardiovascular drugs in developing nations has played directly into the strengths of Indian manufacturers.

Future Outlook

With the domestic market projected to reach USD 130 billion by 2030, the export momentum is expected to accelerate. Stakeholders are now focusing on “Non-Tariff Barrier” negotiations and Mutual Recognition Agreements (MRAs) to ensure that the 45-day approval cycles recently implemented at home are mirrored by faster entry into partner nations.